December 2017 Quarterly Report
Filed with ASX · · 8 pages · English
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Prospectus
- Early Efficacy & Safety Data Planned for XanADu Trial
- Placement Fully Funds Completion of XanADu Alzheimers Trial
- R&D Rebate Received Totalling $1.22 Million
- Quarterly Update & Appendix 4C
Later from Actinogen Medical
- New Data Supports Cortisol Hypothesis
- Strong Recruitment Progress in Alzheimers Trial
- Mid-Way Point Reached in Landmark Alzheimers Trial - XanADu
- March 2018 Quarterly Report
- XanADu Interim Analysis-Continuation Without Change
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical